Accessibility/Mobile Features
Skip Navigation
Skip to Content
Editorial News
Business
Classified Sites

The Canadian Press - ONLINE EDITION

Switzerland's Roche to buy InterMune, US-based developer of lung disease drugs, in $8.3B deal

FILE - In this June 6, 2011 file picture, the logo of Swiss drugmaker Roche is photographed in Rotkreuz, Switzerland. Roche Holding AG . Swiss pharmaceutical company Roche says it will buy InterMune, Inc., a California-based developer of treatments for lung diseases, in a deal worth US $8.3 billion. Roche said SundayAug. 24, 2014 the companies have reached an agreement under which Roche will acquire InterMune in an all-cash transaction, with Roche paying US$ 74.00 per InterMune share. That’s a premium of 38 percent over InterMune’s closing price on Friday. (AP Photo/Keystone/Urs Flueeler, File)

Enlarge Image

FILE - In this June 6, 2011 file picture, the logo of Swiss drugmaker Roche is photographed in Rotkreuz, Switzerland. Roche Holding AG . Swiss pharmaceutical company Roche says it will buy InterMune, Inc., a California-based developer of treatments for lung diseases, in a deal worth US $8.3 billion. Roche said SundayAug. 24, 2014 the companies have reached an agreement under which Roche will acquire InterMune in an all-cash transaction, with Roche paying US$ 74.00 per InterMune share. That’s a premium of 38 percent over InterMune’s closing price on Friday. (AP Photo/Keystone/Urs Flueeler, File)

BERLIN - Swiss pharmaceutical company Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California-based developer of treatments for lung diseases.

The companies have reached an agreement under which Roche will acquire InterMune in an all-cash transaction, paying $74.00 per InterMune share, Roche said. That is a premium of 38 per cent over InterMune's closing price on Friday.

The acquisition of the biotechnology company, based in Brisbane, California, "will allow Roche to broaden and strengthen its respiratory portfolio globally," the Swiss company said. It added that the transaction is expected to bolster earnings from 2016.

Roche said it plans "a smooth transition of InterMune employees and operations into the Roche organization." The American company hopes to launch its drug pirfenidone in the U.S. later this year.

The drug is designed to treat a terminal lung disease called idiopathic pulmonary fibrosis, or IPF, which causes inflammation and scarring of the lung that makes it hard for patients to breathe. InterMune began selling it in Europe under the name Esbriet in 2011 and it is also available in Canada and some other countries.

  • Rate this Rate This Star Icon
  • This article has not yet been rated.
  • We want you to tell us what you think of our articles. If the story moves you, compels you to act or tells you something you didn’t know, mark it high. If you thought it was well written, do the same. If it doesn’t meet your standards, mark it accordingly.

    You can also register and/or login to the site and join the conversation by leaving a comment.

    Rate it yourself by rolling over the stars and clicking when you reach your desired rating. We want you to tell us what you think of our articles. If the story moves you, compels you to act or tells you something you didn’t know, mark it high.

Sort by: Newest to Oldest | Oldest to Newest | Most Popular 0 Commentscomment icon

You can comment on most stories on brandonsun.com. You can also agree or disagree with other comments. All you need to do is register and/or login and you can join the conversation and give your feedback.

There are no comments at the moment. Be the first to post a comment below.

Post Your Commentcomment icon

Comment
  • You have characters left

The Brandon Sun does not necessarily endorse any of the views posted. Comments are moderated before publication. By submitting your comment, you agree to our Terms and Conditions. New to commenting? Check out our Frequently Asked Questions.

letters

Make text: Larger | Smaller

Brandon Sun Business Directory
The First World War at 100
Why Not Minot?
Welcome to Winnipeg

Social Media

Canadian Mortgage Rates